Concepedia

Teodora Trasieva

TT

Statistics

Publications

4

Citations

356

H-Index

4

Active since

2018

Affiliations

AstraZeneca (United States)(Current)

AstraZeneca (Sweden)

The Ohio State University

Cliniques Universitaires Saint-Luc

University of Cambridge

Teodora Trasieva is an author at AstraZeneca (United States) specializing in rheumatology, immunomodulatory drug therapy, and systemic lupus erythematosus.

Publications per year

2018–2023

4

Publications

4

Phase II randomised trial of type I interferon inhibitor anifrolumab in patients with active lupus nephritis

David Jayne, Brad H. Rovin, Eduardo Mysler et al. · Annals of the Rheumatic Diseases · 2022 · 194 citations · Full text

, , +12

Lupus Low Disease Activity State (LLDAS) attainment discriminates responders in a systemic lupus erythematosus trial: post-hoc analysis of the Phase IIb MUSE trial of anifrolumab

Eric F. Morand, Teodora Trasieva, Anna Berglind et al. · Annals of the Rheumatic Diseases · 2018 · 95 citations · Full text

, , +17

Anifrolumab in lupus nephritis: results from second-year extension of a randomised phase II trial

David Jayne, Brad H. Rovin, Eduardo Mysler et al. · Lupus Science & Medicine · 2023 · 51 citations · Full text

, , +17

POS0690 RANDOMIZED, CONTROLLED, PHASE 2 TRIAL OF TYPE 1 IFN INHIBITOR ANIFROLUMAB IN PATIENTS WITH ACTIVE PROLIFERATIVE LUPUS NEPHRITIS

David Jayne, B.H. Rovin, Eduardo Mysler et al. · Annals of the Rheumatic Diseases · 2021 · 16 citations · Full text

, , +17

1–4 of 4